UroGen Pharma’s (URGN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a report issued on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock.

Several other equities research analysts also recently weighed in on the company. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $43.70.

UroGen Pharma Stock Performance

NASDAQ URGN opened at $10.39 on Wednesday. UroGen Pharma has a 52 week low of $9.78 and a 52 week high of $20.70. The company has a 50 day moving average price of $11.50 and a 200 day moving average price of $13.21. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the previous year, the firm posted ($0.68) earnings per share. Equities research analysts predict that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On UroGen Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new stake in shares of UroGen Pharma during the second quarter worth about $719,000. Millennium Management LLC boosted its holdings in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after buying an additional 1,119,019 shares during the last quarter. Barclays PLC raised its holdings in shares of UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after acquiring an additional 48,040 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of UroGen Pharma by 120.3% in the second quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after acquiring an additional 1,337,257 shares in the last quarter. Finally, Wesbanco Bank Inc. acquired a new stake in shares of UroGen Pharma in the third quarter worth approximately $945,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.